QuidelOrtho Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that QuidelOrtho Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.73B | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $2.78B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.00B | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $3.27B | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $1.70B | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $1.66B | Feb 23, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($1.13B) | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | ($2.05B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($10.10M) | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $548.70M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $704.20M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $810.30M | Feb 23, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($919.20M) | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | ($1.96B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $139.10M | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $843.70M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $906.00M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $1.06B | Feb 23, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $186.20M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $218.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $245.00M | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $187.90M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $95.70M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $84.30M | Feb 23, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $746.30M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $766.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $763.20M | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $621.00M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $239.60M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $180.70M | Feb 23, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $105.20M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $83.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $280.20M | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $885.30M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $805.90M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $629.70M | Feb 23, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $188.20M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $195.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $209.30M | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $140.90M | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $292.80M | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | $64.90M | Feb 23, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $5.77B | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $6.42B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $8.56B | Feb 27, 2025 |
| FY2023 | Jan 1, 2023 | $8.86B | Aug 1, 2024 |
| FY2022 | Jan 2, 2022 | $2.43B | Feb 23, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $3.85B | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $3.44B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.56B | Feb 27, 2025 |
| FY2023 | Jan 1, 2023 | $3.92B | Aug 1, 2024 |
| FY2022 | Jan 2, 2022 | $501.00M | Feb 23, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $1.92B | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $2.98B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $5.01B | Feb 19, 2026 |
| FY2025 | Jan 1, 2023 | $4.93B | Feb 19, 2026 |
| FY2024 | Jan 2, 2022 | $1.93B | Feb 27, 2025 |
| FY2023 | Jan 3, 2021 | $1.33B | Aug 1, 2024 |
| FY2022 | Dec 29, 2019 | $559.90M | Feb 23, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $0 | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $649.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.49B | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | $2.48B | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | $337.00M | Aug 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($996.00M) | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $135.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.19B | Feb 27, 2025 |
| FY2023 | Jan 1, 2023 | $2.20B | Aug 1, 2024 |
| FY2022 | Jan 2, 2022 | $1.65B | Feb 23, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $169.80M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | $98.30M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $118.90M | Feb 27, 2025 |
| FY2023 | Jan 1, 2023 | $292.90M | Aug 1, 2024 |
| FY2022 | Jan 2, 2022 | $802.80M | Feb 23, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.70B | Feb 19, 2026 |
| FY2024 | Dec 29, 2024 | $2.49B | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $2.42B | Aug 1, 2024 |
| FY2022 | Jan 1, 2023 | $2.65B | Feb 23, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | (16) | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | (30) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | 9 | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | 16 | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | 19 | Feb 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | (16) | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | (30) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Jan 1, 2023 | 9 | Feb 27, 2025 |
| FY2023 | Jan 2, 2022 | 16 | Aug 1, 2024 |
| FY2022 | Jan 3, 2021 | 18 | Feb 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 67.90M | Feb 19, 2026 |
| FY2025 | Dec 29, 2024 | 67.30M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 66.70M | Feb 27, 2025 |
| FY2023 | Jan 1, 2023 | 66.40M | Aug 1, 2024 |
| FY2022 | Jan 2, 2022 | 41.70M | Feb 23, 2023 |